钠-葡萄糖共转运蛋白2抑制剂可减少慢性乙型肝炎糖尿病患者的肝脏事件

GastroHep Pub Date : 2021-07-01 DOI:10.1002/ygh2.471

L. Y. Liang, V. Wong, Vicki Wing-Ki Hui, T. Yip, Y. Tse, G. Lui, H. Chan, G. Wong

{"title":"钠-葡萄糖共转运蛋白2抑制剂可减少慢性乙型肝炎糖尿病患者的肝脏事件","authors":"L. Y. Liang, V. Wong, Vicki Wing-Ki Hui, T. Yip, Y. Tse, G. Lui, H. Chan, G. Wong","doi":"10.1002/ygh2.471","DOIUrl":null,"url":null,"abstract":"Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) are a novel class of anti‐diabetic drugs that lower the blood glucose level by inhibiting the renal glucose reabsorption. We aimed to evaluate the effect of SGLT2i on the risk of hepatic events in diabetic patients with chronic hepatitis B (CHB).","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"35 1","pages":"261 - 269"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B\",\"authors\":\"L. Y. Liang, V. Wong, Vicki Wing-Ki Hui, T. Yip, Y. Tse, G. Lui, H. Chan, G. Wong\",\"doi\":\"10.1002/ygh2.471\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) are a novel class of anti‐diabetic drugs that lower the blood glucose level by inhibiting the renal glucose reabsorption. We aimed to evaluate the effect of SGLT2i on the risk of hepatic events in diabetic patients with chronic hepatitis B (CHB).\",\"PeriodicalId\":12480,\"journal\":{\"name\":\"GastroHep\",\"volume\":\"35 1\",\"pages\":\"261 - 269\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GastroHep\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/ygh2.471\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GastroHep","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/ygh2.471","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

钠葡萄糖共转运蛋白2抑制剂(SGLT2i)是一类新型的抗糖尿病药物，通过抑制肾脏葡萄糖重吸收来降低血糖水平。我们的目的是评估SGLT2i对糖尿病合并慢性乙型肝炎(CHB)患者肝脏事件风险的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Sodium‐glucose co‐transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B

Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) are a novel class of anti‐diabetic drugs that lower the blood glucose level by inhibiting the renal glucose reabsorption. We aimed to evaluate the effect of SGLT2i on the risk of hepatic events in diabetic patients with chronic hepatitis B (CHB).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

GastroHep

自引率

0.00%

发文量